Post-earnings recap
Reported
Tue, Nov 6, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
The earnings report indicates that Protagonist Therapeutics is still in a developmental phase, with no revenue reported. The stock's positive reaction, rising 9.58%, suggests that investors are optimistic about the company's clinical progress and future potential, despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management remains cautiously optimistic about the company's future, emphasizing progress in clinical development. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing progress in clinical trials.
They expressed confidence in upcoming data releases.
No specific guidance was provided for future quarters.
Est. EPS
—
Est. Rev
—
Impl. Move
—